Literature DB >> 12925560

Endothelin-A receptors mediate renal hemodynamic effects of exogenous Angiotensin II in humans.

Alberto Montanari1, Almerina Biggi, Nicoletta Carra, Maurizio Ziliotti, Elena Fasoli, Luisa Musiari, Patrizia Perinotto, Almerico Novarini.   

Abstract

To investigate whether endothelin-A receptors mediate hemodynamic changes caused by exogenous Angiotensin II in humans, 7 healthy volunteers on a 250-mmol sodium diet underwent 3 separate p-aminohippurate and inulin-based renal hemodynamic studies. In 2 studies, Angiotensin II (increasing rates of 0.625, 1.25, and 2.5 ng/kg per minute, each for 30 minutes) was infused either alone or combined with endothelin-A blocker, BQ123, 0.4 nmol/kg per minute. A third infusion of BQ123 alone was not followed by any change. Angiotensin II infusion alone produced a progressive decrease in renal blood flow (1080+/-94 mL/minx1.73 m2 to 801+/-52, P<0.001, versus baseline) and glomerular filtration rate (115+/-7 mL/minx1.73 m2 to 97+/-7, P<0.001) with increase in filtration fraction (0.188+/-.017 to 0.220+/-.030, P<0.01). Mean arterial pressure and renal vascular resistance increased markedly (86.8+/-3.1 to 97.5+/-4.4 mm Hg, P<0.001 and 83+/-7 to 133+/-20 mm Hg/min per liter, P<0.001, respectively). With Angiotensin II+BQ 123, mean arterial pressure still rose (86.2+/-3.1 to 91.1+/-4.3, P<0.05 versus both baseline and BQ123 alone) but significantly less than with Angiotensin II alone (P<0.05). Renal blood flow (1077+/-76 to 993+/-79, P<0.001) and glomerular filtration rate (115+/-7 to 105+/-7, P<0.05) also changed to a significantly lesser extent than with Angiotensin II alone (P<0.05 for both), whereas filtration fraction remained unchanged (0.185+/-.015 to 0.186+/-.016). Renal vascular resistance rose only by 17% (82+/-5 to 95+/-9, P<0.001 versus baseline as well as versus BQ123 or Angiotensin II alone). The results show that endothelin through Endothelin-A receptors contributes substantially to the systemic and renal vasoconstriction of low-dose exogenous Angiotensin II in healthy humans.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12925560     DOI: 10.1161/01.HYP.0000088361.26773.08

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  4 in total

1.  Pivotal role of mouse mast cell protease 4 in the conversion and pressor properties of Big-endothelin-1.

Authors:  Martin Houde; Marc-David Jamain; Julie Labonté; Louisane Desbiens; Gunnar Pejler; Michael Gurish; Shinji Takai; Pedro D'Orléans-Juste
Journal:  J Pharmacol Exp Ther       Date:  2013-04-17       Impact factor: 4.030

Review 2.  Endothelin-receptor antagonists in arterial hypertension: further indications?

Authors:  Isabella Sudano; Matthias Hermann; Frank T Ruschitzka
Journal:  Curr Hypertens Rep       Date:  2007-03       Impact factor: 4.592

3.  Cyclooxygenase-2 Inhibition Limits Angiotensin II-Induced DNA Oxidation and Protein Nitration in Humans.

Authors:  Vincent Pialoux; Marc J Poulin; Brenda R Hemmelgarn; Daniel A Muruve; Erica N Chirico; Camille Faes; Darlene Y Sola; Sofia B Ahmed
Journal:  Front Physiol       Date:  2017-03-10       Impact factor: 4.566

4.  Pioglitazone Modulates the Vascular Contractility in Hypertension by Interference with ET-1 Pathway.

Authors:  Roberto Palacios-Ramírez; Raquel Hernanz; Angela Martín; José V Pérez-Girón; María T Barrús; Zoe González-Carnicero; Andrea Aguado; Frederic Jaisser; Ana M Briones; Mercedes Salaices; María J Alonso
Journal:  Sci Rep       Date:  2019-11-11       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.